Letermovir
Letermovir
Letermovir (pronunciation: leh-ter-mo-veer) is an antiviral medication used in the prevention of Cytomegalovirus (CMV) infection in individuals who have undergone an Allogeneic hematopoietic stem cell transplantation (HSCT).
Etymology
The name "Letermovir" is derived from the systematic chemical name of the drug, which is (S)-[[2-(4-fluorophenyl)-1,5,6,7-tetrahydro-6-(1H-1,2,3-triazol-1-ylmethyl)-4H-pyrrolo[3,4-d]pyrimidin-4-one]]. The "-vir" suffix is common in antiviral medications, indicating its use in viral infections.
Usage
Letermovir is used as a prophylactic treatment to prevent the development of CMV infection in individuals who have undergone an HSCT. It works by inhibiting the CMV DNA terminase complex, which is essential for viral replication.
Related Terms
- Cytomegalovirus: A type of herpesvirus that can cause disease in individuals with weakened immune systems.
- Allogeneic hematopoietic stem cell transplantation: A procedure in which a person receives blood-forming stem cells from a genetically similar, but not identical, donor.
- DNA terminase complex: An enzyme complex that plays a crucial role in the replication of viral DNA.
Side Effects
Common side effects of Letermovir include nausea, diarrhea, vomiting, peripheral edema, cough, headache, fatigue, and abdominal pain.
See Also
External links
- Medical encyclopedia article on Letermovir
- Wikipedia's article - Letermovir
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski